Safety and Effectiveness of the Single-Use Coronary Forward Intravascular Lithotripsy Catheter Combined With the Intravascular Lithotripsy Therapy Device

NCT ID: NCT07109479

Last Updated: 2025-08-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-01
• Study Completion Date: 2027-12-31

Brief Summary

The FORWARD IVL trial is a Prospective, Multicenter Study conducted to assess the safety and effectiveness of the Single-Use Coronary Forward Intravascular Lithotripsy Catheter combined with the Intravascular Lithotripsy Therapy Device for the pre-treatment of calcified, stenotic de novo coronary artery lesions .

Detailed Description

The approved IVL devices are based on balloon design, and the biggest limitation is the crossability, especially in the severe stenosis lesions.

Coronary Forward IVL Catheter allow the catheter to modify calcium in tight, difficult to cross lesions to increase the compliance of the vessel and allow further crossing of the device or additional treatment.

This trial consists of two parts:

Part 1 (RCT part): this part is a prospective, multicenter, randomized controlled, study in subjects with moderate-to-severe calcification.180 eligible subjects are planned to enroll .

Part 2 (Single-arm part):This part is a single-arm study in subjects with calcified lesions that are Chronic Total Occlusions (CTOs)(with minimum 30 subjects).

Conditions

Coronary Arterial Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Intravascular Lithotripsy

Group Type: EXPERIMENTAL

Intravascular Lithotripsy

Intervention Type: DEVICE

study group will receive the investigational devices (Single-Use Coronary Forward Intravascular Lithotripsy Catheter combined with the Intravascular Lithotripsy Therapy Device) for calcified lesion pre-treatment.

Coronary Rotational Atherectomy

Group Type: ACTIVE_COMPARATOR

Rotational Atherectomy

Intervention Type: DEVICE

control group will receive the control device (Coronary Rotational Atherectomy System)

Interventions

Intravascular Lithotripsy

study group will receive the investigational devices (Single-Use Coronary Forward Intravascular Lithotripsy Catheter combined with the Intravascular Lithotripsy Therapy Device) for calcified lesion pre-treatment.

Intervention Type: DEVICE

Rotational Atherectomy

control group will receive the control device (Coronary Rotational Atherectomy System)

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 1) Age ≥18 years, male or female.

2)Primary coronary artery disease (with evidence of asymptomatic myocardial ischemia, stable/unstable angina, or old MI) scheduled for non-emergent PCI.

3)Pre-procedure Left Ventricular Ejection Fraction (LVEF) ≥30%.

4)Voluntarily participate in this study and sign Informed Consent Form (ICF), willing to comply with study procedures and follow-up.

1. Target lesion is de novo calcified stenotic coronary lesion with no prior intervention.

2. Target lesion reference vessel diameter is 2.5-4.0 mm.

3. Target lesion meets ONE of the following:

RCT part: Moderate-to-severe calcification AND stenosis ≥90% and <100% (length ≤60 mm). (Moderate Calcification: Clearly visible high-density shadows during cardiac motion; Severe Calcification: Clearly visible high-density shadows visible without cardiac motion).

Single-arm part: Calcified lesion AND Chronic Total Occlusion (CTO) (length ≤20 mm).

4. Guidewire positioned in the true lumen distal to the target lesion and not in the subintimal space prior to device use.

Exclusion Criteria

• 1) Planning use of scoring/cutting balloons, Excimer Laser Coronary Atherectomy (ELCA), or Coronary Intravascular Lithotripsy balloons for calcified lesion modification prior to study device use.

2) NYHA Class III or IV.

3) Currently on dialysis or serum creatinine level >2.5 mg/dL (or 221 µmol/L).

4) Severe coagulation disorder (platelet count <100×10⁹/L).

5) Hyperviscosity diseases (e.g., polycythemia vera, platelet count >750×10⁹/L).

6) Cardiac shock with clinical signs or symptoms.

7) Active systemic infection.

8) Moderate-to-severe anemia (hemoglobin <90 g/L).

9) Acute Myocardial Infarction within 1 month prior to procedure.

10) Stroke or Transient Ischemic Attack (TIA) within 3 months prior to procedure.

11) Active gastrointestinal ulcer or bleeding within 3 months prior to procedure.

12) Expected life expectancy <12 months as assessed by the investigator.

13) Known intolerance to antiplatelet or anticoagulant therapy.

14) Known allergy to study device components or contrast media.

15) Known pregnancy or lactation (female subjects).

16) Participating or planning to participate in another drug or device clinical trial.

17) Other conditions deemed unsuitable for participation by the investigator

1. Unprotected left main coronary artery disease (stenosis >50%).

2. Serious angiographic complication in the target vessel prior to study device use.

3. Presence of thrombus or suspected thrombus in the target vessel.

4. Aneurysm within 10 mm of the target lesion in the target vessel.

5. Presence of other lesions with stenosis >50% within the target vessel.

6. CTO lesion with excessive tortuosity (>45°) or length >20 mm.

7. Stent implanted within 5 mm proximal or distal to the target lesion.

8. Target lesion accessible only via saphenous vein graft (SVG) or arterial graft.

9. Failure of guidewire to successfully cross the target lesion.

10. Planned use of Antegrade Dissection Re-entry (ADR), Retrograde Wiring (RW), or Retrograde Dissection Re-entry (RDR) techniques

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Spectrumedics Medical Technology(Shanghai)Co.,Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

Countries

China

Central Contacts

Fei Yu

Role: CONTACT

fei.yu@spectrumedics.com

15996030368

Other Identifiers

PC-SWFC-01

Identifier Type: -

Identifier Source: org_study_id